Quan ZheFeng, Tian Ming, Chi Ping, Li Xin, He HaiLi, Luo Chao
Department of Anesthesiology, Beijing You An Hospital, Capital Medical University, Beijing, 100069, China.
PLoS One. 2015 May 13;10(5):e0125014. doi: 10.1371/journal.pone.0125014. eCollection 2015.
To observe the hemodynamic changes of parturients in the combined use of hyperbaric (4 mg) and hypobaric (6 mg) ropivacaine during spinal anesthesia for caesarean section in this randomized double-blind study.
Parturients (n = 136) undergoing elective cesarean delivery were randomly and equally allocated to receive either combined hyperbaric and hypobaric ropivacaine (Group A) or hyperbaric ropivacaine (Group B). Outcome measures were: hemodynamic characteristics, maximum height of sensory block, time to achieve T8 sensory blockade level, incidence of complications, Apgar scores at 1 and 5 min, and neonatal blood gas analysis.
Group A had a lower level of sensory blockade (T6 [T6-T7]) and longer time to achieve T8 sensory blockade level (8 ± 1.3 min) than did patients in Group B (T3 [T2-T4] and 5 ± 1.0 min, respectively; P < 0.001, both). The incidence rates for hypotension, nausea, and vomiting were significantly lower in Group A (13%, 10%, and 3%, respectively) than Group B (66%, 31%, and 13%; P < 0.001, P = 0.003, P = 0.028).
Combined use of hyperbaric (4 mg) and hypobaric (6 mg) ropivacaine significantly decreased the incidences of hypotension and complications in spinal anesthesia for caesarean section by extending induction time and decreasing the level of sensory blockade.
Chinese Clinical Trial Register ChiCTR-TRC-13004622.
在这项随机双盲研究中,观察剖宫产脊髓麻醉期间高压(4毫克)和低压(6毫克)罗哌卡因联合使用时产妇的血流动力学变化。
将接受择期剖宫产的产妇(n = 136)随机等分为接受高压和低压罗哌卡因联合使用的组(A组)或高压罗哌卡因组(B组)。观察指标包括:血流动力学特征、感觉阻滞的最大高度、达到T8感觉阻滞水平的时间、并发症发生率、1分钟和5分钟时的阿氏评分以及新生儿血气分析。
与B组患者相比,A组的感觉阻滞水平较低(T6 [T6 - T7]),达到T8感觉阻滞水平的时间较长(分别为8 ± 1.3分钟),而B组为T3 [T2 - T4]和5 ± 1.0分钟;两者均P < 0.001)。A组低血压、恶心和呕吐的发生率显著低于B组(分别为13%、10%和3%),而B组为66%、31%和13%;P < 0.001、P = 0.003、P = 0.028)。
高压(4毫克)和低压(6毫克)罗哌卡因联合使用可通过延长诱导时间和降低感觉阻滞水平,显著降低剖宫产脊髓麻醉中低血压和并发症的发生率。
中国临床试验注册中心ChiCTR - TRC - 13004622。